Join to View Full Profile
450 Brookline av, Dana 929Boston, MA 02115
Phone+1 617-632-5456
Fax+1 617-632-2167
Dr. Choueiri is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Toni Choueiri is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Dana-Farber Cancer Institute. He received his medical degree from St Joseph's University Medical School and has been in practice 17 years. He also speaks multiple languages, including Arabic and French. He specializes in genitourinary oncology (kidney, prostate, bladder and testicular cancers). He is a Professor of Medicine at Harvard Medical School.
Education & Training
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2004 - 2007- Cleveland Clinic FoundationResidency, Internal Medicine, 2001 - 2004
St Joseph's University Medical SchoolClass of 2000
Certifications & Licensure
MA State Medical License 2006 - 2027
NH State Medical License 2024 - 2026
RI State Medical License 2020 - 2020
OH State Medical License 2001 - 2011
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2015, 2017
- CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2013-2015, 2017
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2013-2015, 2017
Clinical Trials
- Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma Start of enrollment: 2008 Dec 01
- Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC Start of enrollment: 2006 Sep 01
- S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
Publications & Presentations
PubMed
- DPP9-mediated inflammasome repression protects against checkpoint inhibitor lung toxicity.J Richard Brewer, Ailin Han, Amin H Nassar, Elias Bou Farhat, Holly N Blackburn
Biorxiv. 2026-07-02 - Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma.Toni K Choueiri, Robert J Motzer, Jose A Karam, Wesley Yip, Cristina Suárez
The New England Journal of Medicine. 2026-07-02 - Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma.Rana R McKay, Michael Serzan, Wanling Xie, Bradley A McGregor, David Braun
Journal for Immunotherapy of Cancer. 2026-07-01
Journal Articles
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell CarcinomaRobert Motzer, Thomas E Hutson, Jaime R Merchan, Corina E Dutcus, Rodolfo F Perini, Toni K Choueiri, The New England Journal of Medicine
- Cancer Screening Tests and Cancer Diagnoses During the COVID-19 PandemicToni Choueiri, MD, JAMA Oncology
- Rethinking Clinical Trials Reform During the COVID-19 PandemicChadi Nabhan, Toni K Choueiri, JAMA Oncology
Lectures
- Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
- A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell ca...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Other
- Efficacy of Savolitinib vs Sunitinib in Patients with MET-Driven Papillary Renal Cell CarcinomaToni Choueiri, MD, JAMA Oncology
https://www.doximity.com/articles/ba81e72a-1a08-424c-9605-ecfc7add2d39
UpToDate, Wolters Kluwer Health - 2013-02-21
Authored Content
- Rethinking Clinical Trials Reform During the COVID-19 PandemicAugust 2020
- Rethinking Clinical Trials Reform During the COVID-19 PandemicAugust 2020
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
Press Mentions
Merck's Welireg-Keytruda Pairing Sticks the Landing in Adjuvant Kidney Cancer Treatment with New FDA NodJune 15th, 2026- Dana-Farber’s Dr. Toni Choueiri Elected to the Association of American PhysiciansApril 20th, 2026
- A New Standard? Merck's Welireg Combos Deliver 1-2 Punch to Kidney CancerFebruary 28th, 2026
Professional Memberships
- Member
Other Languages
- Arabic, French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
